Clinical use of thymidine as a rescue agent from methotrexate toxicity

Jean L. Grem, Susan A. King, J. Mel Sorensen, Michaele C. Christian

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Thymidine has been available for clinical research as a rescue agent since 1978 under sponsorship of the Division of Cancer Treatment, National Cancer Institute. Renal insufficiency following administration of high dose methotrexate results in prolonged exposure to toxic concentrations of drug. Thymidine has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. The outcome of eight cases in which thymidine was released under the special exception mechanism to treat patients who developed acute renal failure following methotrexate are reported. The clinical trials using thymidine in combination with methotrexate in patients with normal renal function are also reviewed.

Original languageEnglish (US)
Pages (from-to)281-290
Number of pages10
JournalInvestigational New Drugs
Volume9
Issue number3
DOIs
StatePublished - Aug 1 1991

Fingerprint

Methotrexate
Thymidine
Kidney
Leucovorin
National Cancer Institute (U.S.)
Poisons
Acute Kidney Injury
Renal Insufficiency
Clinical Trials
Research
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • high-dose methotrexate
  • thymidine rescue

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical use of thymidine as a rescue agent from methotrexate toxicity. / Grem, Jean L.; King, Susan A.; Sorensen, J. Mel; Christian, Michaele C.

In: Investigational New Drugs, Vol. 9, No. 3, 01.08.1991, p. 281-290.

Research output: Contribution to journalReview article

Grem, Jean L. ; King, Susan A. ; Sorensen, J. Mel ; Christian, Michaele C. / Clinical use of thymidine as a rescue agent from methotrexate toxicity. In: Investigational New Drugs. 1991 ; Vol. 9, No. 3. pp. 281-290.
@article{fe834c6a77dd4c35b9e7d86215a3792f,
title = "Clinical use of thymidine as a rescue agent from methotrexate toxicity",
abstract = "Thymidine has been available for clinical research as a rescue agent since 1978 under sponsorship of the Division of Cancer Treatment, National Cancer Institute. Renal insufficiency following administration of high dose methotrexate results in prolonged exposure to toxic concentrations of drug. Thymidine has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. The outcome of eight cases in which thymidine was released under the special exception mechanism to treat patients who developed acute renal failure following methotrexate are reported. The clinical trials using thymidine in combination with methotrexate in patients with normal renal function are also reviewed.",
keywords = "high-dose methotrexate, thymidine rescue",
author = "Grem, {Jean L.} and King, {Susan A.} and Sorensen, {J. Mel} and Christian, {Michaele C.}",
year = "1991",
month = "8",
day = "1",
doi = "10.1007/BF00176985",
language = "English (US)",
volume = "9",
pages = "281--290",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Clinical use of thymidine as a rescue agent from methotrexate toxicity

AU - Grem, Jean L.

AU - King, Susan A.

AU - Sorensen, J. Mel

AU - Christian, Michaele C.

PY - 1991/8/1

Y1 - 1991/8/1

N2 - Thymidine has been available for clinical research as a rescue agent since 1978 under sponsorship of the Division of Cancer Treatment, National Cancer Institute. Renal insufficiency following administration of high dose methotrexate results in prolonged exposure to toxic concentrations of drug. Thymidine has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. The outcome of eight cases in which thymidine was released under the special exception mechanism to treat patients who developed acute renal failure following methotrexate are reported. The clinical trials using thymidine in combination with methotrexate in patients with normal renal function are also reviewed.

AB - Thymidine has been available for clinical research as a rescue agent since 1978 under sponsorship of the Division of Cancer Treatment, National Cancer Institute. Renal insufficiency following administration of high dose methotrexate results in prolonged exposure to toxic concentrations of drug. Thymidine has been used in conjunction with leucovorin and alkaline hydration to protect patients with acute renal dysfunction from life-threatening methotrexate toxicity. The outcome of eight cases in which thymidine was released under the special exception mechanism to treat patients who developed acute renal failure following methotrexate are reported. The clinical trials using thymidine in combination with methotrexate in patients with normal renal function are also reviewed.

KW - high-dose methotrexate

KW - thymidine rescue

UR - http://www.scopus.com/inward/record.url?scp=0025752749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025752749&partnerID=8YFLogxK

U2 - 10.1007/BF00176985

DO - 10.1007/BF00176985

M3 - Review article

C2 - 1838364

AN - SCOPUS:0025752749

VL - 9

SP - 281

EP - 290

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -